AR109450A1 - Moléculas de unión a ilt7 y métodos de uso de las mismas - Google Patents

Moléculas de unión a ilt7 y métodos de uso de las mismas

Info

Publication number
AR109450A1
AR109450A1 ARP170100775A ARP170100775A AR109450A1 AR 109450 A1 AR109450 A1 AR 109450A1 AR P170100775 A ARP170100775 A AR P170100775A AR P170100775 A ARP170100775 A AR P170100775A AR 109450 A1 AR109450 A1 AR 109450A1
Authority
AR
Argentina
Prior art keywords
polynucleotide
ilt7
host cell
seq
binding molecule
Prior art date
Application number
ARP170100775A
Other languages
English (en)
Inventor
Miguel Angel Sanjuan
Melissa Marie Damschroder
Julie Ann Douthwaite
Katherine Ann Vousden
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of AR109450A1 publication Critical patent/AR109450A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Abstract

Reivindicación 1: Una proteína de unión a ILT7 aislada, caracterizada porque se puede unir al mismo epitope de ILT7 que un anticuerpo que comprende una región variable de la cadena pesada (VH) de la SEQ ID Nº 202 y una región variable de la cadena liviana (VL) de la SEQ ID Nº 207. Reivindicación 29: Un polinucleótido aislado, caracterizado porque comprende un ácido nucleico que codifica una VH, en donde la VH comprende una secuencia de aminoácidos que es por lo menos 85%, 90%, 95% idéntica, o es idéntica a la VH de la SEQ ID Nº 202, 12, 22, 32, 42, 52, 62, 72, 82, 92, 102, 112, 122, 132, 142, 152, 162, 172, 182, 192, 212, 222, 232 ó 242. Reivindicación 38: Una célula huésped, caracterizada porque fue transformada con el polinucleótido de la reivindicación 29 ó 30 y el polinucleótido de la reivindicación 31 ó 32. Reivindicación 43: Un método para producir una molécula de unión anti-ILT7, caracterizado porque comprende cultivar la célula huésped de cualquiera de las reivindicaciones 38 - 42 y recuperar dicha molécula de unión. Reivindicación 47: Una composición farmacéutica, caracterizada porque comprende (a) la molécula de unión a ILT7 de cualquiera de las reivindicaciones 1 - 27 ó 44, el polinucleótido de cualquiera de las reivindicaciones 29 - 35, el vector de la reivindicación 36, el polipéptido de la reivindicación 37 o la célula huésped de la reivindicación 28 ó 38 - 42 y (b) un vehículo. Reivindicación 50: Un método para prevenir una enfermedad autoinmune en un sujeto humano, caracterizado porque comprende administrar al sujeto una cantidad eficaz de la molécula de unión de cualquiera de las reivindicaciones 1 - 27 ó 44, el polinucleótido de cualquiera de las reivindicaciones 29 - 35, el vector de la reivindicación 36, el polipéptido de la reivindicación 37, la célula huésped de la reivindicación 28 ó 38 - 42 o la composición de la reivindicación 47.
ARP170100775A 2016-03-10 2017-03-29 Moléculas de unión a ilt7 y métodos de uso de las mismas AR109450A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662306125P 2016-03-10 2016-03-10

Publications (1)

Publication Number Publication Date
AR109450A1 true AR109450A1 (es) 2018-12-12

Family

ID=59790876

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP170100775A AR109450A1 (es) 2016-03-10 2017-03-29 Moléculas de unión a ilt7 y métodos de uso de las mismas
ARP210101444A AR122196A2 (es) 2016-03-10 2021-05-28 Proteína de unión a ilt7, célula huésped, polinucleótido, vector, y métodos relacionados

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP210101444A AR122196A2 (es) 2016-03-10 2021-05-28 Proteína de unión a ilt7, célula huésped, polinucleótido, vector, y métodos relacionados

Country Status (17)

Country Link
US (3) US11072652B2 (es)
EP (1) EP3426298A4 (es)
JP (3) JP6979976B2 (es)
KR (4) KR102439395B1 (es)
CN (2) CN109414499B (es)
AR (2) AR109450A1 (es)
AU (1) AU2017231833B2 (es)
BR (1) BR112018067951A2 (es)
CA (1) CA3017197A1 (es)
IL (1) IL261653A (es)
MX (1) MX2018010771A (es)
RU (1) RU2756109C2 (es)
SG (2) SG11201807523PA (es)
TW (1) TWI755380B (es)
UA (1) UA127731C2 (es)
WO (1) WO2017156298A1 (es)
ZA (1) ZA201806597B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2756109C2 (ru) 2016-03-10 2021-09-28 Виела Байо, Инк. Связывающие ilt7 молекулы и способы их применения
WO2018119425A2 (en) * 2016-12-22 2018-06-28 Icahn School Of Medicine At Mount Sinai Anti-lilrb3 antibodies and methods of use thereof
AU2020257252A1 (en) * 2019-04-19 2021-10-14 Allogene Therapeutics, Inc. Antibodies against 4G7-derived chimeric antigen receptors
KR20220110523A (ko) * 2019-12-06 2022-08-08 비엘라 바이오, 인크. Ilt7 결합 단백질을 사용하는 치료 방법
BR112022011957A2 (pt) * 2019-12-20 2022-09-06 Medimmune Llc Composições e métodos de tratamento de câncer com receptores de antígenos quiméricos visando glipicana 3
WO2021203013A2 (en) * 2020-04-03 2021-10-07 Viela Bio, Inc. Methods of treating immune mediated pulmonary injury
EP4333877A1 (en) 2021-05-04 2024-03-13 Viela Bio, Inc. Methods of treatment of autoimmune disorders using ilt7 binding proteins
TW202404640A (zh) 2022-07-27 2024-02-01 美商維埃拉生物股份有限公司 包含免疫球蛋白樣轉錄本７（ｉｌｔ７）結合蛋白之調配物

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2096948A (en) 1935-12-20 1937-10-26 Anchor Steel & Conveyor Co Conveyer system
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
JP3771253B2 (ja) 1988-09-02 2006-04-26 ダイアックス コープ． 新規な結合タンパク質の生成と選択
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
EP0564531B1 (en) 1990-12-03 1998-03-25 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
EP0580737B1 (en) 1991-04-10 2004-06-16 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
PT1231268E (pt) 1994-01-31 2005-11-30 Univ Boston Bancos de anticorpos policlonais
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
DE4440354A1 (de) 1994-11-11 1996-05-15 Hoechst Schering Agrevo Gmbh Kombinationen aus Phenylsulfonylharnstoff-Herbiziden und Safenern
US6706484B1 (en) 1995-08-18 2004-03-16 Morphosys Ag Protein/(poly)peptide libraries
WO1997008320A1 (en) 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Protein/(poly)peptide libraries
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ES2353268T3 (es) 1999-07-02 2011-02-28 Morphosys Ag Generacion de elementos de union especifica que se unen a (poli)peptidos codificados por fragmentos de adn genomico o est.
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
NZ520392A (en) 2000-02-10 2005-04-29 Abbott Lab Antibodies that bind human interleukin-18 and methods of making and using
US6897067B2 (en) 2000-11-03 2005-05-24 Regents Of The University Of Michigan Surface transfection and expression procedure
DE60126130T2 (de) 2000-11-17 2007-10-18 The University Of Rochester In-vitro verfahren zur herstellung und identifizierung von immunglobulin moleküle in eukaryotischen zellen
WO2003012061A2 (en) * 2001-08-01 2003-02-13 Coley Pharmaceutical Gmbh Methods and compositions relating to plasmacytoid dendritic cells
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
WO2003081376A2 (en) 2002-03-20 2003-10-02 Catalina Marketing International Inc. Targeted incentives based upon predicted behavior
NZ571508A (en) 2002-05-24 2010-05-28 Schering Corp Neutralizing human anti-IGFR antibody
AU2003289716A1 (en) 2002-09-12 2004-04-30 Incyte Corporation Molecules for diagnostics and therapeutics
CA2532781A1 (en) 2003-07-18 2005-01-27 Mochida Pharmaceutical Co., Ltd The anti-platelet membrane glycoprotein vi monoclonal antibody
US9208495B2 (en) 2003-10-06 2015-12-08 Yellowpages.Com Llc Methods and apparatuses for advertisement presentation
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
BRPI0607490A2 (pt) 2005-02-10 2009-09-08 Baylor Res Inst anticorpos monoclonais antiinterferon alfa e métodos para uso
WO2006124269A2 (en) 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
EP1964852B1 (en) 2005-12-20 2013-04-17 SBI Biotech Co., Ltd. Anti-ilt7 antibody
AU2012244391B2 (en) 2005-12-20 2014-09-11 Sbi Biotech Co., Ltd. Anti-ILT7 antibody
KR20090029184A (ko) * 2006-04-07 2009-03-20 더 가브먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 항체 조성물 및 신생물성 질병의 치료 방법
MX2008013993A (es) 2006-05-03 2009-05-11 Univ Colorado Combinación adyuvante sinergistica de anticuerpo agonista de cd40/interferona tipo 1, conjugados que la contienen y uso de los mismos como un terapeutico para aumentar la inmunidad celular.
US7781306B2 (en) 2007-06-20 2010-08-24 Semiconductor Energy Laboratory Co., Ltd. Semiconductor substrate and method for manufacturing the same
WO2010065536A2 (en) 2008-12-01 2010-06-10 The Board Of Regents Of The University Of Texas System Recombinant bone marrow stromal antigen-2 in the treatment of autoimmune diseases
PT2473636T (pt) 2009-09-03 2017-02-06 Medimmune Llc Diagnóstico de interferão de tipo-1
EP2496600A1 (en) 2009-11-04 2012-09-12 Fabrus LLC Methods for affinity maturation-based antibody optimization
AR086074A1 (es) 2011-04-26 2013-11-13 Genentech Inc Composiciones y metodo para tratar enfermedades autoinmunes
PT2702146T (pt) 2011-04-28 2019-04-22 Univ Leland Stanford Junior Identificação de polinucleótidos associados a uma amostra
US9427464B2 (en) 2011-11-22 2016-08-30 Chiome Bioscience Inc. Anti-human TROP-2 antibody having an antitumor activity in vivo
HUE054362T2 (hu) * 2012-01-31 2021-09-28 Sbi Biotech Co Ltd Foszfolipáz D4 elleni antitest
US8605807B1 (en) 2012-05-22 2013-12-10 Nigel Iain Stuart Macrae Communicating distinct data over a single frequency using multiple linear polarized signals
BR112015010566A2 (pt) * 2012-11-08 2017-07-11 Clearside Biomedical Inc métodos e dispositivos para o tratamento de doenças oculares em indivíduos humanos
US9114438B2 (en) 2013-05-21 2015-08-25 Applied Materials, Inc. Copper residue chamber clean
MA40528A (fr) * 2014-08-29 2017-07-05 Sorrento Therapeutics Inc Anticorps thérapeutiques qui se lient à oprf et oprl
RU2756109C2 (ru) 2016-03-10 2021-09-28 Виела Байо, Инк. Связывающие ilt7 молекулы и способы их применения
KR20220110523A (ko) 2019-12-06 2022-08-08 비엘라 바이오, 인크. Ilt7 결합 단백질을 사용하는 치료 방법
EP4333877A1 (en) 2021-05-04 2024-03-13 Viela Bio, Inc. Methods of treatment of autoimmune disorders using ilt7 binding proteins

Also Published As

Publication number Publication date
KR102632796B1 (ko) 2024-02-02
US20200339673A1 (en) 2020-10-29
UA127731C2 (uk) 2023-12-20
KR20230148266A (ko) 2023-10-24
US11072652B2 (en) 2021-07-27
RU2756109C2 (ru) 2021-09-28
KR102603010B1 (ko) 2023-11-16
JP6979976B2 (ja) 2021-12-15
JP2022043038A (ja) 2022-03-15
SG11201807523PA (en) 2018-09-27
CN109414499A (zh) 2019-03-01
KR20180138201A (ko) 2018-12-28
JP2024009808A (ja) 2024-01-23
CN109414499B (zh) 2022-05-17
RU2018135550A3 (es) 2020-07-23
AU2017231833A1 (en) 2018-10-11
SG10202008769SA (en) 2020-10-29
JP2019516392A (ja) 2019-06-20
MX2018010771A (es) 2019-05-15
WO2017156298A1 (en) 2017-09-14
BR112018067951A2 (pt) 2019-02-05
EP3426298A4 (en) 2019-11-27
TW201742874A (zh) 2017-12-16
CA3017197A1 (en) 2017-09-14
KR20220123344A (ko) 2022-09-06
AU2017231833B2 (en) 2024-03-14
CN114874322A (zh) 2022-08-09
RU2018135550A (ru) 2020-04-10
IL261653A (en) 2018-10-31
KR20240017421A (ko) 2024-02-07
AR122196A2 (es) 2022-08-24
TWI755380B (zh) 2022-02-21
EP3426298A1 (en) 2019-01-16
KR102439395B1 (ko) 2022-09-05
ZA201806597B (en) 2023-04-26
US20230250167A1 (en) 2023-08-10
US20220144940A1 (en) 2022-05-12
JP7354212B2 (ja) 2023-10-02
US11673950B2 (en) 2023-06-13

Similar Documents

Publication Publication Date Title
AR109450A1 (es) Moléculas de unión a ilt7 y métodos de uso de las mismas
PE20191463A1 (es) Anticuerpos biespecificos de union especifica pd1 y lag3
AR091069A1 (es) Proteinas de union a antigeno dirigidas contra el receptor st2
CL2019001926A1 (es) Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017).
EA201792045A1 (ru) Новый комплекс, содержащий проникающий в клетку пептид, карго-молекулу и пептидный агонист tlr
AR117727A1 (es) Anticuerpos que se unen a cd3
EA202091710A1 (ru) Антитела против cd73 и способы их применения
AR108034A1 (es) Moléculas de unión a ror1, y métodos de uso de las mismas
ES2689080T3 (es) Anticuerpos que se unen a TL1A y sus usos
AR063829A1 (es) Moleculas de enlace de lingo y uso farmaceutico de las mismas
AR102554A1 (es) Receptores quiméricos de antígeno anti-cldn y métodos de uso
PE20171654A1 (es) Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer
PE20240096A1 (es) Anticuerpos biespecificos especificos para un receptor de tnf coestimulador
PE20181044A1 (es) Anticuerpos anti-pd-1 y composiciones
PE20190450A1 (es) Anticuerpos anti-pd-1, un metodo de produccion y un metodo para su uso
AR110979A1 (es) Moléculas de unión a cd70 y métodos de uso de las mismas
PE20211300A1 (es) Peptidos y combinacion de peptidos de origen no canonico para el uso en la inmunoterapia contra diferentes tipos de cancer
DOP2019000011A (es) Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123
AR077088A1 (es) Proteinas biespecificas de union a antigeno
MX2017004117A (es) Moleculas de enlace, especialmente anticuerpos, enlazadas a l1cam(cd171).
BR112014001573B8 (pt) Molécula fv ao antígeno multivalente
WO2017193094A8 (en) Dna monoclonal antibodies targeting checkpoint molecules
AR046833A1 (es) Anticuerpos anti-interleuquina-10
AR096617A1 (es) Anticuerpos anti-tweakr y sus usos
AR095240A1 (es) ANTICUERPOS ANTI-TGF-b MODIFICADOS POR INGENIERÍA GENÉTICA Y FRAGMENTOS DE UNIÓN A ANTÍGENOS